-
Homepage -
Online Submission
- Artificial Intelligence in Cancer
- Artificial Intelligence in Gastroenterology
- Artificial Intelligence in Gastrointestinal Endoscopy
- Artificial Intelligence in Medical Imaging
- World Journal of Anesthesiology
- World Journal of Biological Chemistry
- World Journal of Cardiology
- World Journal of Clinical Cases
- World Journal of Clinical Infectious Diseases
- World Journal of Clinical Oncology
- World Journal of Clinical Pediatrics
- World Journal of Clinical Urology
- World Journal of Critical Care Medicine
- World Journal of Dermatology
- World Journal of Diabetes
- World Journal of Experimental Medicine
- World Journal of Gastroenterology
- World Journal of Gastrointestinal Endoscopy
- World Journal of Gastrointestinal Oncology
- World Journal of Gastrointestinal Pathophysiology
- World Journal of Gastrointestinal Pharmacology and Therapeutics
- World Journal of Gastrointestinal Surgery
- World Journal of Hematology
- World Journal of Hepatology
- World Journal of Hypertension
- World Journal of Immunology
- World Journal of Medical Genetics
- World Journal of Meta-Analysis
- World Journal of Methodology
- World Journal of Nephrology
- World Journal of Neurology
- World Journal of Obstetrics and Gynecology
- World Journal of Ophthalmology
- World Journal of Orthopedics
- World Journal of Otorhinolaryngology
- World Journal of Pharmacology
- World Journal of Psychiatry
- World Journal of Radiology
- World Journal of Respirology
- World Journal of Rheumatology
- World Journal of Stem Cells
- World Journal of Stomatology
- World Journal of Surgical Procedures
- World Journal of Translational Medicine
- World Journal of Transplantation
- World Journal of Virology
- 世界华人消化杂志
| For: | Mak LY, Seto WK, Lai CL, Yuen MF. An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. Expert Opin Drug Metab Toxicol 2018;14:483-91. [PMID: 29718748 DOI: 10.1080/17425255.2018.1472236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis] |
|---|
| Number | Citing Articles |
| 1 | Torgersen J, Taddei TH, Lo Re V. Reply to: “Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?”. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.02.025] [Reference Citation Analysis] |
| 2 | Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V 3rd. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. J Hepatol 2021:S0168-8278(21)01950-4. [PMID: 34333102 DOI: 10.1016/j.jhep.2021.07.021] [Reference Citation Analysis] |
| 3 | Miao M, Jing X, De Clercq E, Li G. Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy. Drug Des Devel Ther 2020;14:2759-74. [PMID: 32764876 DOI: 10.2147/DDDT.S254754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis] |
| 4 | Solitano V, Plaz Torres MC, Pugliese N, Aghemo A. Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? Viruses 2021;13:1048. [PMID: 34205966 DOI: 10.3390/v13061048] [Reference Citation Analysis] |